A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.
Cancer communications (London, England)（2023）
Key words
non‐small‐cell non‐small‐cell lung cancer,mefatinib,non‐small‐cell lung cancer,lung cancer,<i>egfr</i>
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined